Skip to content
Screener

MiMedx Group MDXG Surgical — Net Sales

Other product segments

Wound
$25.07M-61.1%

Similar metrics at other companies

Enovis logo
ENOVSurgical — Net Sales
$294.53M+7.5%
Edwards Lifesciences logo
EWSurgical — Net Sales
$284.1M—
The Cooper Companies, Inc. logo
COOOffice and surgical — Net Sales
$214.2M+4.1%
Medtronic logo
MDTMedical Surgical — Net Sales
$2.39B+8.0%
AVN
AVNSSurgical pain and recovery — Net Sales
$21.8M-11.0%
Medline, Inc. logo
MDLNSurgical Solutions — Net Sales
$1.64B+8.7%

Other financials

Income statement

See full
Revenue$64.4M-34.7%
Gross profit$44.4M-44.5%
Operating income-$18.5M-249%
Net income-$14.8M-254%
EPS (diluted)-$0.10-267%

Balance sheet

See full
Cash & equivalents$135.8M+14.3%
Total debt$17.2M-6.8%
Total equity$216.0M-0.3%
Total assets$281.0M-3.5%

Cash flow

See full
Operating cash flow-$10.0M-169%
CapEx$598.0K+234%
Free cash flow-$10.6M-175%

Valuation

See full
Market cap$632.6M-39.3%
Enterprise value$513.97M-45.4%
P/E101.4×+69.0×
P/S1.8×-1.1×

Profitability

See full
Gross margin78.8%-2.6pp
Operating margin2.5%-9.3pp
Net margin1.8%-7.1pp
FCF margin12.5%-3.2pp

Returns & leverage

See full
Return on equity2.9%-13.8pp
Debt / equity0.1×0.0×
Current ratio5.3×+0.9×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: MiMedx Group’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001376339-26-000071
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Surgical$39,29734,12975,67166,261
Wound25,06564,47647,682120,549
Net sales$64,362$98,605$123,353$186,810

Item 1. Financial Statements

FAQ

What is MiMedx Group's surgical — net sales?
MiMedx Group (MDXG) reported surgical — net sales of $39.3M in Q2 2026.
How has MiMedx Group's surgical — net sales changed year-over-year?
MiMedx Group's surgical — net sales increased by 15.1% year-over-year, from $34.13M to $39.3M.
What is the long-term trend for MiMedx Group's surgical — net sales?
Over 3 years (2022 to 2025), MiMedx Group's surgical — net sales has grown at a 15.7% compound annual growth rate (CAGR), from $91.87M to $142.3M.
What does surgical — net sales mean?
This metric represents the total revenue generated from the sale of regenerative biomaterials and bioimplants specifically utilized within surgical, sports medicine, and orthopedic clinical applications. It serves as a key indicator of the company's market penetration and adoption rates for internal-use allografts and related surgical products. Growth in this segment reflects the company's ability to expand its footprint in high-acuity medical procedures and compete effectively within the broader surgical intervention market.

Ask your AI about MiMedx Group's surgical — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude